dexrazoxane has been researched along with Sarcoma, Epithelioid in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Badalamenti, G; Improta, L; Mazzocca, A; Napolitano, A; Santini, D; Silletta, M; Spalato Ceruso, M; Tonini, G; Valeri, S; Vincenzi, B | 1 |
| Benjamin, RS; Minotti, G | 1 |
| Busemann, C; Ehninger, G; Gerdes, S; Hentschel, L; Kopp, HG; Lenz, F; Pink, D; Reichardt, P; Richter, S; Schuler, MK; West, A | 1 |
3 other study(ies) available for dexrazoxane and Sarcoma, Epithelioid
| Article | Year |
|---|---|
Use of Cardioprotective Dexrazoxane Is Associated with Increased Myelotoxicity in Anthracycline-Treated Soft-Tissue Sarcoma Patients.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Dexrazoxane; Female; Hematologic Diseases; Humans; Male; Middle Aged; Neutropenia; Protective Agents; Retrospective Studies; Sarcoma; Young Adult | 2019 |
Doxorubicin-Dexrazoxane from Day 1 for Soft-tissue Sarcomas: The Road to Cardioprotection.
Topics: Cardiotoxicity; Dexrazoxane; Doxorubicin; Humans; Razoxane; Sarcoma | 2021 |
Efficacy and safety of Dexrazoxane (DRZ) in sarcoma patients receiving high cumulative doses of anthracycline therapy - a retrospective study including 32 patients.
Topics: Adolescent; Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cardiotoxicity; Dexrazoxane; Disease-Free Survival; Female; Free Radical Scavengers; Heart; Humans; Male; Middle Aged; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Young Adult | 2016 |